WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
UNAIDS/WHO 2015 | Reference
PLOS ONE | https://doi.org/10.1371/journal.pone.0192765 February 23, 2018
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Accountability for the global health sector strategies, 2016–2021
WHO/CDS/HIV/19.7
International Journal of Infectious Diseases 80 (2019) 10–15
journal homepage: www.elsevier.com/locate/ijid
Technical Report
AIDS Medicines and diagnostics service
September 2016
World Health Organization Department of Reproductive Health and Research
Brocher Foundation, Hermance, Geneva, Switzerland, 27–29 April 2016
htb supplement: 2018 Vol 19:(1)
New drugs in development
July 2018
www.i-Base.info
Research Article
Hindawi
BioMed Research International
Volume 2018, Article ID 9619684, 10 pages https://doi.org/10.1155/2018/9619684